Patents Assigned to Nykode Therapeutics ASA
-
Patent number: 11780924Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.Type: GrantFiled: June 21, 2017Date of Patent: October 10, 2023Assignees: UNIVERSITY OF OSLO, NYKODE THERAPEUTICS ASAInventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
-
Publication number: 20230303718Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: February 2, 2023Publication date: September 28, 2023Applicant: NYKODE THERAPEUTICS ASAInventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
-
Publication number: 20230293650Abstract: The present invention relates to an individualized therapeutic anticancer vaccine, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine.Type: ApplicationFiled: April 9, 2021Publication date: September 21, 2023Applicant: Nykode Therapeutics ASAInventors: Agnete Brunsvik Fredriksen, Monika Sekelja, Karoline Schjetne, Stine Granum
-
Publication number: 20230165952Abstract: Disclosed is a vaccine comprising an immunologically effective amount of a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit and an antigenic unit, wherein the antigenic unit comprises at least one betacoronavirus epitope. The vaccine is ideal for pandemic and epidemics as it can induce rapid, strong immune response with lower/fewer doses because the antigen is targeted to antigen presenting cells and the antigen is produced in the body.Type: ApplicationFiled: May 3, 2021Publication date: June 1, 2023Applicant: Nykode Therapeutics ASAInventors: Agnete Brunsvik Fredriksen, Monika Sekelja, Karoline Schjetne, Gunnstein Norheim, Elisabeth Stubsrud
-
Publication number: 20230065226Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: ApplicationFiled: September 22, 2022Publication date: March 2, 2023Applicant: Nykode Therapeutics ASAInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Publication number: 20230048561Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: March 8, 2022Publication date: February 16, 2023Applicant: NYKODE THERAPEUTICS ASAInventors: Bjarne BOGEN, Agnete B. FREDRICKSEN, Inger SANDLIE
-
Publication number: 20220370579Abstract: The present invention relates to an anticancer vaccine which includes polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine includes a polynucleotide with a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit. The antigenic unit includes from 3 to 50 antigenic subunits separated by a second linker with each antigenic subunit having at least a part of a cancer neoepitope sequence. The vaccine can include a polypeptide encoded by the polynucleotide or a dimeric protein with two polypeptides encoded by the polynucleotide.Type: ApplicationFiled: December 21, 2021Publication date: November 24, 2022Applicant: NYKODE THERAPEUTICS ASAInventors: Stine Granum, Elisabeth Stubsrud, Agnete Brunsvik Fredriksen
-
Patent number: 11479605Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: GrantFiled: February 7, 2020Date of Patent: October 25, 2022Assignee: Nykode Therapeutics ASAInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen